187 related articles for article (PubMed ID: 24511053)
1. Clinical characteristics of advanced hepatocellular carcinoma patients with prolonged survival in the era of anti-angiogenic targeted-therapy.
Lu LC; Shao YY; Chan SY; Hsu CH; Cheng AL
Anticancer Res; 2014 Feb; 34(2):1047-52. PubMed ID: 24511053
[TBL] [Abstract][Full Text] [Related]
2. Molecular targeted therapies in hepatocellular carcinoma.
Tanaka S; Arii S
Semin Oncol; 2012 Aug; 39(4):486-92. PubMed ID: 22846865
[TBL] [Abstract][Full Text] [Related]
3. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma.
Shao YY; Lin ZZ; Hsu C; Shen YC; Hsu CH; Cheng AL
Cancer; 2010 Oct; 116(19):4590-6. PubMed ID: 20572033
[TBL] [Abstract][Full Text] [Related]
4. Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy.
Shao YY; Wu CH; Lu LC; Chan SY; Ma YY; Yen FC; Hsu CH; Cheng AL
J Hepatol; 2014 Feb; 60(2):313-8. PubMed ID: 24036008
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models.
Baek KK; Kim JH; Uhm JE; Park SH; Lee J; Park JO; Park YS; Kang WK; Lim HY
Oncology; 2011; 80(3-4):167-74. PubMed ID: 21701230
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma.
Shao YY; Lin ZZ; Hsu C; Lee KD; Hsiao CH; Lu YS; Huang CC; Shen YC; Hsu CH; Cheng AL
Oncology; 2012; 82(1):59-66. PubMed ID: 22310088
[TBL] [Abstract][Full Text] [Related]
7. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
Pang RW; Poon RT
Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
[TBL] [Abstract][Full Text] [Related]
8. Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science.
Weintraub JL; Salem R
J Vasc Interv Radiol; 2013 Aug; 24(8):1123-34. PubMed ID: 23562168
[TBL] [Abstract][Full Text] [Related]
9. Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: current status and future perspectives.
Zhu AX
Semin Oncol; 2012 Aug; 39(4):493-502. PubMed ID: 22846866
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib.
Pinter M; Sieghart W; Hucke F; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Matejka J; Stauber R; Buder R; Grünberger B; Schöniger-Hekele M; Müller C; Peck-Radosavljevic M
Aliment Pharmacol Ther; 2011 Oct; 34(8):949-59. PubMed ID: 21883324
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma.
Yau T; Chan P; Wong H; Ng KK; Chok SH; Cheung TT; Lam V; Epstein RJ; Fan ST; Poon RT
Oncology; 2007; 72 Suppl 1():67-71. PubMed ID: 18087184
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy.
Estfan B; Byrne M; Kim R
Am J Clin Oncol; 2013 Aug; 36(4):319-24. PubMed ID: 22547010
[TBL] [Abstract][Full Text] [Related]
13. The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.
Wörns MA; Koch S; Niederle IM; Marquardt JU; Nguyen-Tat M; Gamstätter T; Schuchmann M; Schulze-Bergkamen H; Galle PR; Weinmann A
Dig Liver Dis; 2013 May; 45(5):408-13. PubMed ID: 23182599
[TBL] [Abstract][Full Text] [Related]
14. A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors.
Song T; Zhang W; Wu Q; Kong D; Ma W
Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1233-8. PubMed ID: 21941188
[TBL] [Abstract][Full Text] [Related]
15. Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials.
Subbiah IM; Falchook GS; Kaseb AO; Hess KR; Tsimberidou AM; Fu S; Subbiah V; Hong DS; Naing A; Piha-Paul SA; Akmal O; Janku F; Kurzrock R
Oncotarget; 2015 Sep; 6(29):28453-62. PubMed ID: 26164085
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma.
Hsu CH; Shen YC; Lin ZZ; Chen PJ; Shao YY; Ding YH; Hsu C; Cheng AL
J Hepatol; 2010 Jul; 53(1):126-31. PubMed ID: 20416968
[TBL] [Abstract][Full Text] [Related]
17. Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma.
Vora SR; Zheng H; Stadler ZK; Fuchs CS; Zhu AX
Oncologist; 2009 Jul; 14(7):717-25. PubMed ID: 19581525
[TBL] [Abstract][Full Text] [Related]
18. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
[TBL] [Abstract][Full Text] [Related]
19. Angiogenesis and anti-angiogenesis in hepatocellular carcinoma.
Ribatti D; Vacca A; Nico B; Sansonno D; Dammacco F
Cancer Treat Rev; 2006 Oct; 32(6):437-44. PubMed ID: 16870349
[TBL] [Abstract][Full Text] [Related]
20. AFP measurement in monitoring treatment response of advanced hepatocellular carcinoma to sorafenib: case report and review of the literature.
Gamstätter T; Weinmann A; Schadmand-Fischer S; Spies PR; Niederle IM; Schuchmann M; Galle PR; Wörns MA
Onkologie; 2011; 34(10):538-42. PubMed ID: 21985853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]